Opendata, web and dolomites

iProg

Tailored cell-based therapies for frontotemporal dementia and related genetically defined CNS orphan indications

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 iProg project word cloud

Explore the words cloud of the iProg project. It provides you a very rough idea of what is the project "iProg" about.

solutions    suffer    company    framework    populations    therapy    standards    game    cns    biotherapeutics    conduct    innovation    repair    changers    implantable    disorders    progranulin    orphan    prepare    biotechnology    tech    diseases    biologics    treatment    degeneration    signals    iia    paving    mutations    lower    desired    safety    device    right    transforming    first    frontotemporal    instrument    exposure    vision    thereby    therapies    modifying    patients    candidates    therapeutic    systemic    leverage    lives    sme    brd    neurodegenerative    driver    pgrn    sinfonia    ultimately    disease    detect    reaching    iprog    ftd    neurotrophic    phasei    brain    manner    locally    market    combat    frame    negligible    clinical    restores    overcome    ing    lay    causative    safe    situ    genetically    severe    efficacious    drug    generation    failing    successful    gene    efficacy    levels    indications    entirely    proprietary    explore    unmet    medical    patient    medicine   

Project "iProg" data sheet

The following table provides information about the project.

Coordinator
SINFONIA BIOTHERAPEUTICS AB 

Organization address
address: HALSOVAGEN 7, NOVUM
city: HUDDINGE
postcode: 141 57
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://www.sinfoniabiotherapeutics.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SINFONIA BIOTHERAPEUTICS AB SE (HUDDINGE) coordinator 50˙000.00

Map

 Project objective

Sinfonia Biotherapeutics is a high-tech biotechnology company. Our vision is to become a main driver in technology innovation for CNS medicine, where we lay the frame-work for entirely novel therapeutic concepts and solutions that combat the unmet medical need of severe CNS conditions, ultimately transforming patient lives. We are developing targeted therapies for genetically defined CNS orphan indications that are built on a proprietary medical device – the Brain Repair Device - that overcome several of the existing challenges associated with the failing clinical development of drug candidates for neurodegenerative diseases today. The BRD is an implantable device that allows for the in situ production of our therapeutic biologics resulting in desired CNS exposure, while the systemic exposure of the therapeutic factor is negligible. We are developing a new generation of tailored biologics for genetically defined disease/patient populations that target the disease locally in the brain. With our therapies we are thus reaching the right patient, with the right treatment, in an efficacious and safe manner. Through the SME Instrument, we will focus on further developing iProg, a novel neurotrophic therapy that restores progranulin levels in the brain of patients that suffer from frontotemporal degeneration due to mutations in the PGRN gene (FTD/PGRN), which results in lower progranulin production and is disease-causative. We will use the SME Instrument funding (Phase 1&2) to prepare and conduct PhaseI/IIa studies to explore the safety and detect the first signals of efficacy of iProg. If successful, the project will set new standards on the biologics for neurodegenerative disease market, paving a way to growth and new potential partnerships for Sinfonia. Our disease-modifying therapies have the potential to leverage an important framework for therapeutic development in neurodegenerative disorders in general and thereby to become real game changers in CNS medicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IPROG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IPROG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More